MedTrace Logo

Registry of Patients Treated With Systemic Mold-Active Triazoles

NCT03066011 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2015

Last updated 2024-10-21

No results posted yet for this study

Summary

The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).

Conditions

  • Invasive Fungal Infection

Interventions

DRUG

Isavuconazonium sulfate

Oral and Intravenous

DRUG

Voriconazole

Oral and Intravenous

DRUG

Posaconazole

Oral and intravenous

Sponsors & Collaborators

  • Astellas Pharma Global Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Senior Medical Director · Astellas Pharma Global Development, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-16
Primary Completion
2020-04-24
Completion
2020-04-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03066011 on ClinicalTrials.gov